drugset / Trial / NCT05651191
To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL
Phase 0
Unknown
9 enrolled
Hrain Biotechnology Co., Ltd.
Second Affiliated Hospital of Nanchang University · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of human CD19 targeted DASH CAR-T Cells injection, and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Timeline
- Start
- 2022-10-21
- Primary completion
- 2024-09-30
- Completion
- 2025-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DASH CAR-T | Cell therapy | 500000 cells | Other |
| Subject | DASH CAR-T | Cell therapy | 1e+07 cells | Other |
| Subject | DASH CAR-T | Cell therapy | 2e+07 cells | Other |